Teva Pharmaceuticals Shifts Focus to Innovative Biopharma Growth

CEO Richard Francis detailed Teva Pharmaceutical Industries Ltd.'s strategic transition from a pure generics firm to a balanced biopharma business during the U.S. All Stars Conference on September 22, 2026. The company reported that its innovative business segment grew 40% in the second quarter, driven primarily by the performance of AUSTEDO and AJOVY.

Teva is targeting a 30% operating margin by 2027, supported by a shift toward high-margin innovative products and projected cost savings of $700 million. The company's pipeline includes the TL1A asset duvakitug and planned early 2025 launches for ecopipam and olanzapine LAI. While the generics business has stabilized with an expected annual growth rate of 1% to 2%, the company is increasing its focus on biosimilars.

Having secured investment-grade ratings from all three major agencies a year ahead of schedule, Teva is redirecting capital from debt reduction toward growth investments and selective share buybacks. Francis explicitly ruled out the return of dividends at this time.